180 related articles for article (PubMed ID: 8895739)
1. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
Gately S; Twardowski P; Stack MS; Patrick M; Boggio L; Cundiff DL; Schnaper HW; Madison L; Volpert O; Bouck N; Enghild J; Kwaan HC; Soff GA
Cancer Res; 1996 Nov; 56(21):4887-90. PubMed ID: 8895739
[TBL] [Abstract][Full Text] [Related]
2. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils.
Scapini P; Nesi L; Morini M; Tanghetti E; Belleri M; Noonan D; Presta M; Albini A; Cassatella MA
J Immunol; 2002 Jun; 168(11):5798-804. PubMed ID: 12023382
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
Gately S; Twardowski P; Stack MS; Cundiff DL; Grella D; Castellino FJ; Enghild J; Kwaan HC; Lee F; Kramer RA; Volpert O; Bouck N; Soff GA
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10868-72. PubMed ID: 9380726
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases generate angiostatin: effects on neovascularization.
Cornelius LA; Nehring LC; Harding E; Bolanowski M; Welgus HG; Kobayashi DK; Pierce RA; Shapiro SD
J Immunol; 1998 Dec; 161(12):6845-52. PubMed ID: 9862716
[TBL] [Abstract][Full Text] [Related]
5. Angiostatin generation by human pancreatic cancer.
O'Mahony CA; Seidel A; Albo D; Chang H; Tuszynski GP; Berger DH
J Surg Res; 1998 Jun; 77(1):55-8. PubMed ID: 9698533
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells.
O'Mahony CA; Albo D; Tuszynski GP; Berger DH
Surgery; 1998 Aug; 124(2):388-93. PubMed ID: 9706163
[TBL] [Abstract][Full Text] [Related]
7. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators.
Westphal JR; Van't Hullenaar R; Geurts-Moespot A; Sweep FC; Verheijen JH; Bussemakers MM; Askaa J; Clemmensen I; Eggermont AA; Ruiter DJ; De Waal RM
Int J Cancer; 2000 Jun; 86(6):760-7. PubMed ID: 10842188
[TBL] [Abstract][Full Text] [Related]
8. Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis.
Hatziapostolou M; Katsoris P; Papadimitriou E
Eur J Pharmacol; 2003 Jan; 460(1):1-8. PubMed ID: 12535853
[TBL] [Abstract][Full Text] [Related]
9. Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.
Binda MM; Matar P; González AD; Rozados VR; Gervasoni SI; Scharovsky OG; Bonfil RD
Int J Cancer; 2002 Jul; 100(1):14-21. PubMed ID: 12115581
[TBL] [Abstract][Full Text] [Related]
10. The accumulation of angiostatin-like fragments in human prostate carcinoma.
Migita T; Oda Y; Naito S; Morikawa W; Kuwano M; Tsuneyoshi M
Clin Cancer Res; 2001 Sep; 7(9):2750-6. PubMed ID: 11555588
[TBL] [Abstract][Full Text] [Related]
11. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance.
O'Reilly MS; Wiederschain D; Stetler-Stevenson WG; Folkman J; Moses MA
J Biol Chem; 1999 Oct; 274(41):29568-71. PubMed ID: 10506224
[TBL] [Abstract][Full Text] [Related]
12. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
O'Reilly MS
EXS; 1997; 79():273-94. PubMed ID: 9002223
[TBL] [Abstract][Full Text] [Related]
13. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells.
Morikawa W; Yamamoto K; Ishikawa S; Takemoto S; Ono M; Fukushi Ji; Naito S; Nozaki C; Iwanaga S; Kuwano M
J Biol Chem; 2000 Dec; 275(49):38912-20. PubMed ID: 10986284
[TBL] [Abstract][Full Text] [Related]
14. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.
Heidtmann HH; Nettelbeck DM; Mingels A; Jäger R; Welker HG; Kontermann RE
Br J Cancer; 1999 Dec; 81(8):1269-73. PubMed ID: 10604721
[TBL] [Abstract][Full Text] [Related]
15. Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen.
Falcone DJ; Khan KM; Layne T; Fernandes L
J Biol Chem; 1998 Nov; 273(47):31480-5. PubMed ID: 9813061
[TBL] [Abstract][Full Text] [Related]
16. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
Stack MS; Gately S; Bafetti LM; Enghild JJ; Soff GA
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):77-84. PubMed ID: 10229661
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen.
Brauer R; Beck IM; Roderfeld M; Roeb E; Sedlacek R
BMC Biochem; 2011 Jul; 12():38. PubMed ID: 21787393
[TBL] [Abstract][Full Text] [Related]
18. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells.
Stathakis P; Fitzgerald M; Matthias LJ; Chesterman CN; Hogg PJ
J Biol Chem; 1997 Aug; 272(33):20641-5. PubMed ID: 9252380
[TBL] [Abstract][Full Text] [Related]
19. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells.
Redlitz A; Daum G; Sage EH
J Vasc Res; 1999; 36(1):28-34. PubMed ID: 10050071
[TBL] [Abstract][Full Text] [Related]
20. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.
Richardson M; Gunawan J; Hatton MW; Seidlitz E; Hirte HW; Singh G
Gynecol Oncol; 2002 Sep; 86(3):279-87. PubMed ID: 12217749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
